Defence Therapeutics Announces Convertible Debenture Conversion
Montreal, Quebec--(Newsfile Corp. - November 21, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), announces that the holders of the Corporation's 8% convertible debentures issued on November 16, 2024 (the "Debentures") have converted all of the principal amount and the accrued interests thereof into an aggregate number of 2,607,600 common
Biotechnology, Pharmaceuticals, Health
2025-11-21 6:03 PM EST | Defence Therapeutics Inc.
FendX Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - November 21, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, is pleased to announce it intends to settle outstanding debts totalling approximately $25,560 owed by the Company to two arms-length consultants for services performed and payable in common share
Technology, Healthcare and Hospitals, Health
2025-11-21 6:00 PM EST | FendX Technologies Inc.
Mobile-health Network Solutions Signs MOU to Secure Two Malaysian AI Data Center Projects; Facilities Intended to Power Expansion of Company's AI Digital Health Platform
Singapore, Singapore--(Newsfile Corp. - November 21, 2025) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or the "Company"), a leading AI HealthTech platform, today announced the signing of a legally binding Memorandum of Understanding (MOU) with PPG PP GRID SDN. BHD. ("PPG") for the acquisition of PPG project companies that own and are developing two high-density AI-optimized data centers in Sarawak, Malaysia. The data centers include a 25MW facility tar
2025-11-21 8:30 AM EST | Mobile-health Network Solutions
Edison Issues Report on Mendus (IMMU)
London, United Kingdom--(Newsfile Corp. - November 21, 2025) - Edison issues report on Mendus (OMX: IMMU). We have updated our investment view on Mendus following its expanded strategy for vididencel to chronic myeloid leukaemia (CML) and a broader acute myeloid leukaemia (AML) population, including chemo-eligible and chemo-ineligible patients, regardless of their measurable residual disease (MRD) status. In our view, this is a bold strategic pivot for a programme nearing Phase III read
Banking / Financial Services, Computer Hardware, Computer Software, Health
2025-11-21 4:50 AM EST | Edison Group
LevelJump Sets Date for Requisitioned Shareholder Meeting
Toronto, Ontario--(Newsfile Corp. - November 20, 2025) - Further to its news release of November 7, 2025, LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company") announces that its board of directors (the "Board") has called an annual and special meeting of shareholders (the "Meeting") to be held on May 26th, 2026 in response to a shareholder requisition (the "Requisition") submitted by Frank Teti and Franmar Properties Ltd. (collectively the "Concerned Shareholders"
Healthcare and Hospitals, Health
2025-11-20 4:15 PM EST | LevelJump Healthcare Corp.
PreveCeutical Provides Clarification of News Release Announcing Update on Plan of Arrangement with BioGene Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its news release of earlier today, the Company wishes to clarify that shareholders of record of November 24, 2025 will be issued new common shares of PreveCeutical and 0.02 of one share of BioGene Therapeutics Inc. About PreveCeutical PreveCeutical is a heal
Biotechnology, Pharmaceuticals, Health
2025-11-20 12:26 PM EST | PreveCeutical Medical Inc.
St. Baldrick's Foundation Awards Nearly $1.2 Million in Grants, Advancing Research and Hope for Kids with Cancer
Los Angeles, California--(Newsfile Corp. - November 20, 2025) - The St. Baldrick's Foundation, the largest charity funder of childhood cancer research grants in the U.S., is proud to announce nearly $1.2 million in new grants, continuing its mission to support research that brings safer, more effective treatments to kids with cancer. This latest round of funding includes nearly $1 million in Infrastructure Grants designed t
2025-11-20 12:00 PM EST | St. Baldrick's Foundation
Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia
Calgary, Alberta--(Newsfile Corp. - November 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option patients suffering from pain, angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, is pleased to announce Dr. William R. Shankle, MS,
Biotechnology, Pharmaceuticals, Health
2025-11-20 9:00 AM EST | Hemostemix Inc.
Conexeu Sciences Signals a Major Breakthrough in 'Personalized Human Tissue Creation'
Reno, Nevada--(Newsfile Corp. - November 20, 2025) - Conexeu Sciences Inc. ("Conexeu" or the "Company"), a biotechnology innovator redefining regenerative medicine through a next-generation collagen-based platform, is pleased to announce that it has achieved a defining milestone in regenerative medicine with the first ever 3D-printed structures made entirely from its patented, functional extracellular matrix (ECM). Using its patented CXU™ platform, the Company has printed bovine-derived
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-20 9:00 AM EST | Conexeu Sciences Inc.
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares
Ontario and Chicago, Illinois--(Newsfile Corp. - November 20, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange has accepted Medexus's notice of intention to make a normal course issuer bid, or NCIB, for its common shares (TSX: MDP). Under the NCIB, Medexus may purchase for cancellation up to 2,983,650 common shares, representing approximately 10% of the public float as defined under TSX rules. As of November 12, 2025, 32
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-20 7:30 AM EST | Medexus Pharmaceuticals Inc.
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its News Releases of September 4, 2025, September 19, 2025, October 10, 2025 and October 20, 2025, the Company announces that it will be completing
Biotechnology, Pharmaceuticals, Health
2025-11-20 7:00 AM EST | PreveCeutical Medical Inc.
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it has completed its previously announced non-brokered private placement (the "Non-Brokered Unit Offering") to certain institutional investors and other acc
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-19 4:26 PM EST | NervGen Pharma Corp.
ADIA Nutrition Inc. to Host Webinar on HSCT for MS and Autoimmune Conditions with HSCT Warriors
Winter Park, Florida--(Newsfile Corp. - November 19, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA) invites all shareholders, supporters, and potential investors to join a live webinar tomorrow, Thursday, November 20, 2025, at 6:30 PM EST, hosted by HSCT Warriors.
Healthcare and Hospitals, Health
2025-11-19 9:30 AM EST | Adia Nutrition Inc.
Edison Issues Report on Tradedoubler (TRAD)
London, United Kingdom--(Newsfile Corp. - November 19, 2025) - Edison issues report on Tradedoubler (OMX: TRAD). Tradedoubler has a strong proposition in performance marketing, with particular strengths in the partner (affiliate) and influencer areas. With the springboard of a leading position in Europe, it is now expanding operations into the US, the largest global advertising market. Its influencer marketing business, Metapic, is well-placed to take advantage of this dynamic and fast-
Banking / Financial Services, Computer Hardware, Computer Software, Health
2025-11-19 8:48 AM EST | Edison Group
Rock Salt Marketing Launches AI SEO Services for LLM Search Visibility
Salt Lake City, Utah--(Newsfile Corp. - November 19, 2025) - Award-winning Utah- and Nashville-based digital marketing agency, Rock Salt Marketing Cooperative, has officially launched its new AI SEO services as an add-on to its traditional SEO program, designed to help businesses nationwide improve visibility and performance across large language models (LLMs).
Real Estate, Travel, Health, Legal
2025-11-19 7:50 AM EST | Rock Salt Marketing Cooperative
Red Light Holland's FDA-Compliant, DEA-Registered Partner Irvine Labs Receives Second, Larger 5kg Psilocybin Shipment via USA Controlled Substances Import Permit
Toronto, Ontario--(Newsfile Corp. - November 19, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, as well as a premium brand of psilocybin truffles in the legal, recreational market within the Netherlands, in compliance with all applicable laws is excited to announce that it has, f
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2025-11-19 7:45 AM EST | Red Light Holland Corp.
Glow Lifetech Achieves Debt-Free Status, Strengthening Balance Sheet and Enhancing Financial Flexibility for Growth
Toronto, Ontario--(Newsfile Corp. - November 19, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce that it has achieved debt-free status, eliminating all outstanding debt and further strengthening its already strong balance sheet and financial flexibility. This milestone marks an important step in Glow's ongoing commitment to disciplined financial management positioning the business for long-term sustainable growth
2025-11-19 7:30 AM EST | Glow Lifetech Corp.
Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology
Montreal, Quebec--(Newsfile Corp. - November 19, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), is pleased to announce a major step forward in the fight against cancer that goes beyond the ADCs current limitations. Following successful presentations and meetings at the World ADC Conference in San Diego with ADC companies as well as
Biotechnology, Pharmaceuticals, Health
2025-11-19 3:15 AM EST | Defence Therapeutics Inc.
Hemostemix Closes CDN$280,594 Private Placement
Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida
Biotechnology, Pharmaceuticals, Health
2025-11-18 5:08 PM EST | Hemostemix Inc.
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it is conducting a non-brokered private placement (the "Non-Brokered Unit Offering") to certain institutional investors and other accredited inves
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-18 4:42 PM EST | NervGen Pharma Corp.